Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease

Abstract

Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. Fi-broScan ® is used for follow-up of fibrosis and steatosis. This single-center study aims to review the distribution of indications by referral to Fi-broScan ® .Materials and Methods: Demographic characteristics, CLD etiologies, and FibroScan ® parameters of the patients who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated.Results: Out of 9345 patients, 4946 (52.93%) were males, and the median age was 48 years. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N=4768, 51.02%), followed by hepatitis B (N=3194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, and CLD etiology, the results revealed that patients with older age (Odds ratio (OR)=2.908; confidence interval (CI)=2.597-3.256; p<0.001) and patients with hepatitis C (OR=2.582; CI=2.168-3.075; p<0.001), alcoholic liver disease (OR=2.019; CI=1.524-2.674, p<0.001), and autoimmune hepatitis (OR=2.138; CI=1.360-3.660, p<0.001) had increased odds of advanced liver fibrosis compared to NAFLD. Conclusion:NAFLD was the most common indication for referral to FibroScan ® .

Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease

“…This clearly shows that NAFLD has emerged as the leading cause for CLD and cACLD in current times. This is also supported by a recent FibroScan‐based study by Eris et al, which similarly reported NAFLD as the leading etiology of liver fibrosis at their center 26 . It is important to highlight as NAFLD can continue to contribute to liver disease progression in patients with other etiologies of CLD, which have been adequately treated 10,27–29 .…”

“…This is also supported by a recent FibroScan-based study by Eris et al, which similarly reported NAFLD as the leading etiology of liver fibrosis at their center. 26 It is important to highlight as NAFLD can continue to contribute to liver disease progression in patients with other etiologies of CLD, which have been adequately treated. 10,[27][28][29] Notably, NAFLD-associated HCC is also markedly on the rise, concurrent with the rise in prevalence of NAFLD.…”

Vibration-controlled transient elastography for non-invasive screening of liver fibrosis and steatosis in Turkish patients with psoriasis: A cross-sectional study

“…The selection of the probe was carried out using an automated selection tool, choosing either the M (frequency: 3.5 Hz) or XL (frequency: 2.5 Hz) probe as required. [ 11 , 12 ] To determine LSM for each patient, a series of 10 consecutive valid measurements were taken (interquartile range-to-median ratio ≤0.3), and the median value was recorded. [ 11 , 12 ] The CAP is an algorithm that relies on the attenuation of ultrasound waves and is accessible through the FibroScan ® system.…”

“…[ 11 , 12 ] To determine LSM for each patient, a series of 10 consecutive valid measurements were taken (interquartile range-to-median ratio ≤0.3), and the median value was recorded. [ 11 , 12 ] The CAP is an algorithm that relies on the attenuation of ultrasound waves and is accessible through the FibroScan ® system. [ 13 , 14 ] In each patient, CAP values were obtained concurrently with LSM values.…”

“…[ 9 , 10 ] The liver stiffness measurement (LSM) serves as a marker for hepatic fibrosis. [ 11 , 12 ] Concurrently, VCTE obtains the controlled attenuation parameter (CAP), an indicator of hepatic steatosis, by assessing the extent of ultrasound signal attenuation as it passes through the liver parenchyma. [ 13 , 14 ] Therefore, VCTE has the potential to function as a comprehensive screening tool that can assess both fibrosis and steatosis, making it an ideal diagnostic option for individuals at risk of liver disease.…”